Mass spectrometry imaging

LSU Mechanical Engineering Professor, AgCenter Receive $10M Grant to Design New Variety of Rice

Retrieved on: 
Tuesday, June 20, 2023
Diet, U.S. Department of Defense Strategy for Operating in Cyberspace, Education, Heat, Atmosphere, NMR, Survival, GHG, Mass spectrometry, Salinity, Natural Resources, LSU, Soil science, Water, Groundwater, LC-MS, Mass spectrometry imaging, Phenotype, Gene, Louisiana State University, Behavior, MALDI, Agriculture

It is the most widely consumed staple food for more than half of the world’s population, which continues to grow each year.

Key Points: 
  • It is the most widely consumed staple food for more than half of the world’s population, which continues to grow each year.
  • With the production of rice increasing, so does the need for water to grow it.
  • In order to not use up nature’s most precious valuable resource—water—one LSU College of Engineering professor is working with the LSU AgCenter to design a new variety of rice that will be able to withstand drought conditions, making rice production fruitful while not exhausting natural resources.
  • Louisiana is the nation’s third-largest rice-producing state behind Arkansas and California, thanks to its warm climate, abundant water, and water-retaining clay soils.

Waters Boosts Resolution and Triples Scan Speed of SELECT SERIES MRT for Metabolomics and MS Imaging

Retrieved on: 
Monday, June 5, 2023
WAT, Mass spectrometry imaging, American Society for Mass Spectrometry, MALDI, University, Waters, ASMS, Urine, Mass spectrometry, DESI, Sheffield Hallam University, Hope, Research, Noetics, Discovery, Scientific Reports, FWHM, SELECT, Metabolomics, Blood, Drug discovery, MRT, UPLC, Waters Corporation, Society, NYSE, Breast cancer, REM, Television, Medical imaging

HOUSTON, June 5, 2023 /PRNewswire/ -- American Society for Mass Spectrometry (ASMS) -- Waters Corporation (NYSE:WAT) today announced new updates to its SELECT SERIES™ MRT System that increases its specificity and utility for UPLC-MS/MS metabolomics and drug discovery applications and for mass spectrometry imaging experiments. The MRT System now offers 50% higher resolution, making it capable of 300,000 FWHM resolution, a 3X faster scan rate, and parts-per-billion mass accuracy.

Key Points: 
  • New resolution enhancement mode (REM) for Waters' multi-reflecting time-of-flight (MRT) mass spectrometer leads to greater specificity and higher sample throughput for metabolomics UPLC™-MS/MS and MS imaging studies.
  • The MRT System now offers 50% higher resolution, making it capable of 300,000 FWHM resolution, a 3X faster scan rate, and parts-per-billion mass accuracy.
  • It is compatible with numerous MS imaging sources including DESI and MALDI, and generates crystal-clear, high-resolution images without compromising mass spectral resolution or accuracy.
  • The new resolution enhancement mode is available as an optional upgrade to currently installed and new SELECT SERIES MRT Systems.

Fluidigm Announces Collaboration Agreement with Imaging CRO ImaBiotech to Increase Biopharma Access to Imaging Mass Cytometry

Retrieved on: 
Thursday, August 5, 2021
Chief executive officer, Research, Trinidad and Tobago Securities and Exchange Commission, Forward-looking statement, United, Industry, Good laboratory practice, Life, Technology, Adoption, Coronavirus, GLP, Annual report, Government, Private Securities Litigation Reform Act, Regulation, Nasdaq, Security (finance), Partnership, Health, Twitter, Microfluidics, Biomarker, GLOBE, Toxicity, Quality of life, Cancer, Mass spectrometry imaging, Regulation Fair Disclosure, SAN, Precision medicine, Immunotherapy, Histology, Social media, CyTOF, Doctor of Philosophy, Drug development, Biotechnology, Disclosure, Environment, LinkedIn, Acquisition, CRO, Disease, Pharmaceutical industry, Medical imaging, Fine chemical

Our customers expressed a need for high-multiplex imaging, and that compelled us to acquire a Hyperion Imaging System to meet market needs.

Key Points: 
  • Our customers expressed a need for high-multiplex imaging, and that compelled us to acquire a Hyperion Imaging System to meet market needs.
  • We are excited for the opportunity to collaborate with Fluidigm in this regard, innovating applications and products, including new panel development, to make Imaging Mass Cytometry an even more powerful tool.
  • Mass cytometry technologies, including CyTOF , Imaging Mass Cytometry and Maxpar Direct, have been used in more than 160 clinical trials, including 10 utilizing IMC.
  • Fluidigm, theFluidigmlogo, CyTOF, Direct, Hyperion, Imaging Mass Cytometry, IMC, and Maxpar, are trademarks and/or registered trademarks ofFluidigm Corporationinthe United Statesand/or other countries.

JEOL and SCiLS Sign a Distribution Agreement for SCiLS Lab MVS Software

Retrieved on: 
Tuesday, June 8, 2021
Science, Software, Other Science, Research, Data management, Technology, University, Education, Mass spectrometry, Science, Natural sciences, Chemistry, Bruker, Mass spectrometry imaging, MVS

JEOL Ltd.(TOKYO:6951) (President & COO Izumi Oi) and SCiLS, a division of Bruker Daltonics, announced that they have concluded a non-exclusive, worldwide distribution agreement for SCiLS Lab MVS software.

Key Points: 
  • JEOL Ltd.(TOKYO:6951) (President & COO Izumi Oi) and SCiLS, a division of Bruker Daltonics, announced that they have concluded a non-exclusive, worldwide distribution agreement for SCiLS Lab MVS software.
  • View the full release here: https://www.businesswire.com/news/home/20210607005273/en/
    The SCiLS Lab has been the software of choice for researchers wanting to gain new insights from mass spectrometry imaging.
  • SCiLS Lab MVS offers all features of SCiLS Lab and it allows the statistical analysis and visualization of mass spectrometry imaging data of virtually unlimited size in two and three spatial dimensions.
  • "SCiLS Lab MVS our software package for vendor-agnostic data analysis offers the broadest possible compatibility for mass spectrometry imaging data of all vendors.

Frontier Diagnostics Initiates Operations Using Imaging Mass Spectrometry for Cancer Detection

Retrieved on: 
Tuesday, December 15, 2020
Instrumental analysis, Mass spectrometry, Ion source, Biochemistry methods, Mass spectrometry imaging, Matrix-assisted laser desorption/ionization, Matrix, MALDI imaging, Iknife

NASHVILLE, Tenn., Dec. 15, 2020 /PRNewswire/ -- Frontier Diagnostics, a cancer diagnostics company, today announced that it has begun developing and validating a clinical assay for melanoma diagnosis, by direct tissue analysis, using matrix-assisted laser desorption/ionization (MALDI) imaging mass spectrometry.

Key Points: 
  • NASHVILLE, Tenn., Dec. 15, 2020 /PRNewswire/ -- Frontier Diagnostics, a cancer diagnostics company, today announced that it has begun developing and validating a clinical assay for melanoma diagnosis, by direct tissue analysis, using matrix-assisted laser desorption/ionization (MALDI) imaging mass spectrometry.
  • Frontier Diagnostics also announced that it has purchased assets from New River Labs, LLC, a company that made significant investments in imaging mass spectrometry diagnostics in recent years.
  • Norris and Caprioli, internationally known for pioneering imaging mass spectrometry, are faculty members at Vanderbilt University and direct the National Resource for Imaging Mass Spectrometry.
  • Frontier Diagnostics holds several patents for the use of imaging mass spectrometry in diagnostics.

IONpath and Bristol Myers Squibb Jointly Author New Laboratory Investigation Article Exploring the Complexities of the Tumor Microenvironment

Retrieved on: 
Tuesday, March 31, 2020
Mibi, Technetium (99mTc) sestamibi, Mass spectrometry imaging, Tumor microenvironment, Natural sciences, Medical specialties, Health care

MENLO PARK, California, March 31, 2020 /PRNewswire/ --IONpath, Inc. today announces that they have jointly authored with Bristol Myers Squibb an article entitled Multiplexed Ion Beam Imaging (MIBI) for Characterization of the Tumor Microenvironment Across Tumor Types for the Nature journal Laboratory Investigation.

Key Points: 
  • MENLO PARK, California, March 31, 2020 /PRNewswire/ --IONpath, Inc. today announces that they have jointly authored with Bristol Myers Squibb an article entitled Multiplexed Ion Beam Imaging (MIBI) for Characterization of the Tumor Microenvironment Across Tumor Types for the Nature journal Laboratory Investigation.
  • Highly detailed mapping of the tumor microenvironment provided an immune profile(fig 1) and spatial organization (fig 2) through a multi-step process that segmented the sample down to the individual cell.
  • However, the implications of this new level of tumor mapping at a cellular level could be far reaching.
  • IONpath is a registered trademark and MIBI & MIBIscope are trademarks of IONpath INC.For Research Use Only.

IONpath and Bristol Myers Squibb Jointly Author New Laboratory Investigation Article Exploring the Complexities of the Tumor Microenvironment

Retrieved on: 
Tuesday, March 31, 2020
Mibi, Technetium (99mTc) sestamibi, Tumor microenvironment, Mass spectrometry imaging, Natural sciences, Health care, Medical specialties

MENLO PARK, Calif., March 31, 2020 /PRNewswire/ --IONpath, Inc. today announces that they have jointly authored with Bristol Myers Squibb an article entitled Multiplexed Ion Beam Imaging (MIBI) for Characterization of the Tumor Microenvironment Across Tumor Types for the Nature journal Laboratory Investigation.

Key Points: 
  • MENLO PARK, Calif., March 31, 2020 /PRNewswire/ --IONpath, Inc. today announces that they have jointly authored with Bristol Myers Squibb an article entitled Multiplexed Ion Beam Imaging (MIBI) for Characterization of the Tumor Microenvironment Across Tumor Types for the Nature journal Laboratory Investigation.
  • Highly detailed mapping of the tumor microenvironment provided an immune profile(fig 1) and spatial organization (fig 2) through a multi-step process that segmented the sample down to the individual cell.
  • However, the implications of this new level of tumor mapping at a cellular level could be far reaching.
  • IONpath is a registered trademark and MIBI & MIBIscope are trademarks of IONpath INC.For Research Use Only.

IONpath Announces Commercial Launch of MIBIscope™—the First Multiplexed Ion Beam Imaging System

Retrieved on: 
Tuesday, November 5, 2019
Oncology, Health, General Health, Radiology, Research, Science, Biotechnology, Mibi, Radiopharmaceuticals, Technetium (99mTc) sestamibi, Mass spectrometry imaging

IONpath, Inc. , a company revolutionizing multiplexed tissue imaging, launched the MIBIscope System , the first commercially available Multiplexed Ion Beam Imaging (MIBI) system.

Key Points: 
  • IONpath, Inc. , a company revolutionizing multiplexed tissue imaging, launched the MIBIscope System , the first commercially available Multiplexed Ion Beam Imaging (MIBI) system.
  • IONpath is showcasing the platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting in Maryland from November 6-10.
  • This method enables higher throughput than existing multiplexed imaging technologies, such as mass cytometry, and is far more sensitive, permitting single-molecule detection.
  • The companys MIBIscope System utilizes Multiplexed Ion Beam Imaging (MIBI) technology, developed at Stanford University, and represents a transformative step forward in molecular pathology.

Fluidigm Launches Imaging Mass Cytometry Immuno-Oncology Panel Kits and Advanced CyTOF Software at the 2019 World Molecular Imaging Congress (WMIC)

Retrieved on: 
Wednesday, September 4, 2019
Branches of biology, Natural sciences, Biology, Cell biology, Clinical pathology, Laboratory techniques, Mass spectrometry, Mass cytometry, Fluidigm, Mass spectrometry imaging, Molecular imaging, Cytometry

SOUTH SAN FRANCISCO, Calif., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), the global leader in highly multiplexed single-scan tissue imaging, today announced the launch of three new Imaging Mass Cytometry Maxpar Human Immuno-Oncology Panel Kits and an advanced CyTOF Software solution at the World Molecular Imaging Congress (WMIC), in Montreal, Canada.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), the global leader in highly multiplexed single-scan tissue imaging, today announced the launch of three new Imaging Mass Cytometry Maxpar Human Immuno-Oncology Panel Kits and an advanced CyTOF Software solution at the World Molecular Imaging Congress (WMIC), in Montreal, Canada.
  • The Hyperion Imaging System enables highly multiplexed cellular phenotyping in tissue and tumor microenvironments, all from a single scan using Imaging Mass Cytometry .
  • Stephanie will share how she is using Imaging Mass Cytometry in conjunction with mass spectrometry imaging (MSI) to gain greater understanding of biological and pathophysiological processes.
  • Fluidigm, the Fluidigm logo, CyTOF, Hyperion, Imaging Mass Cytometry, IMC, and Maxpar are trademarks and/or registered trademarks of Fluidigm Corporation in the United States and/or other countries.

Journal Cell Features New Immunohistochemistry Imaging Technology from IONpath that Images 40+ Proteins on a Single Slide

Retrieved on: 
Monday, September 10, 2018
Bristol-Myers Squibb, Radiopharmaceuticals, Technetium (99mTc) sestamibi, Technetium-99m, Mass spectrometry imaging

This study will also be shared during a webinar presented by Dr. Mike Angelo on October 2nd, 2018.

Key Points: 
  • This study will also be shared during a webinar presented by Dr. Mike Angelo on October 2nd, 2018.
  • MIBI technology was invented in Prof. Garry Nolan's lab and developed by Drs.
  • The MIBI images collected are shared online and can be downloaded through a web-interface MIBItracker software available on the IONpath company website.
  • ABOUT: IONpath is a venture-backed, commercial-stage company, founded by Stanford researchers out of the lab of Dr. Garry Nolan, focused on revolutionizing pathology with Multiplexed Ion Beam Imaging (MIBI) technology.